Targeting disease in the developing world

A new report by the Access to Medicine Index finds pharmaceutical companies influence access to medicines in developing countries through the development of innovative and adapted products, operating equitable pricing strategies and building local capacity.


Endemic diseases being targeted

Source: Data and insight, Access to Medicine Index 2014

More than half of the 327 products in development at the 20 largest pharmaceutical companies target five conditions; broadly reflecting the focus of available products, although new treatments are now being developed for several neglected diseases.


Pipeline and marketed products

Source: Data and insight, Access to Medicine Index 2014

The vast majority of products applicable to developing countries are for infectious diseases. Although there are several drugs for non-communicable diseases in development, most companies struggle to demonstrate how these products will be accessible to patients in developing countries.


Regulatory approvals

Source: Data and insight, Access to Medicine Index 2014

Since 2012, 11 companies have been granted regulatory approval by the US Food and Drug Administration or the European Medicines Agency for 30 new products for diseases relevant to developing countries


Burden of the top five diseases

Source: World Health Organization

Among these five commonly targeted diseases, the communicable diseases have a higher burden in poorer countries. However, the burden of disease for the non-communicable conditions targeted is shared more equally.


Capacity building

Source: Data and insight, Access to Medicine Index 2014

The 20 largest research-based pharmaceutical companies are active in 75 developing countries in at least one of four areas: research and development; quality management in manufacturing; supply chain management; and pharmacovigilance.


Pricing and donation

Source: Data and insight, Access to Medicine Index 2014

Eighteen of the 20 largest research-based pharmaceutical companies have implemented equitable pricing strategies for developing countries and 15 engage in structured donation programmes.


Pricing and donation

Source: Data and insight, Access to Medicine Index 2014

Eighteen of the 20 largest research-based pharmaceutical companies have implemented equitable pricing strategies for developing countries and 15 engage in structured donation programmes.

Pricing and donation

Source: Data and insight, Access to Medicine Index 2014

Eighteen of the 20 largest research-based pharmaceutical companies have implemented equitable pricing strategies for developing countries and 15 engage in structured donation programmes.

 

Pricing and donation

Source: Data and insight, Access to Medicine Index 2014

Eighteen of the 20 largest research-based pharmaceutical companies have implemented equitable pricing strategies for developing countries and 15 engage in structured donation programmes.

Last updated
Citation
The Pharmaceutical Journal, PJ, 20/27 December 2014, Vol 293, No 7841/2;293(7841/2):DOI:10.1211/PJ.2014.20067466